These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
531 related articles for article (PubMed ID: 24275630)
1. Taking diabetes to heart--deregulation of myocardial lipid metabolism in diabetic cardiomyopathy. Bayeva M; Sawicki KT; Ardehali H J Am Heart Assoc; 2013 Nov; 2(6):e000433. PubMed ID: 24275630 [No Abstract] [Full Text] [Related]
2. Inhibition of sarcolemmal FAT/CD36 by sulfo-N-succinimidyl oleate rapidly corrects metabolism and restores function in the diabetic heart following hypoxia/reoxygenation. Mansor LS; Sousa Fialho MDL; Yea G; Coumans WA; West JA; Kerr M; Carr CA; Luiken JJFP; Glatz JFC; Evans RD; Griffin JL; Tyler DJ; Clarke K; Heather LC Cardiovasc Res; 2017 Jun; 113(7):737-748. PubMed ID: 28419197 [TBL] [Abstract][Full Text] [Related]
3. Lipid metabolism and its implications for type 1 diabetes-associated cardiomyopathy. Ritchie RH; Zerenturk EJ; Prakoso D; Calkin AC J Mol Endocrinol; 2017 May; 58(4):R225-R240. PubMed ID: 28373293 [TBL] [Abstract][Full Text] [Related]
4. Metabolic abnormalities of the heart in type II diabetes. Amaral N; Okonko DO Diab Vasc Dis Res; 2015 Jul; 12(4):239-48. PubMed ID: 25941161 [TBL] [Abstract][Full Text] [Related]
5. Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine. Chen WJY; Diamant M; de Boer K; Harms HJ; Robbers LFHJ; van Rossum AC; Kramer MHH; Lammertsma AA; Knaapen P Cardiovasc Diabetol; 2017 May; 16(1):67. PubMed ID: 28526033 [TBL] [Abstract][Full Text] [Related]
6. MECHANISMS IN ENDOCRINOLOGY: Diabetic cardiomyopathy: pathophysiology and potential metabolic interventions state of the art review. Levelt E; Gulsin G; Neubauer S; McCann GP Eur J Endocrinol; 2018 Apr; 178(4):R127-R139. PubMed ID: 29440374 [TBL] [Abstract][Full Text] [Related]
7. Suppression of plasma free fatty acids reduces myocardial lipid content and systolic function in type 2 diabetes. Wolf P; Winhofer Y; Krssak M; Smajis S; Harreiter J; Kosi-Trebotic L; Fürnsinn C; Anderwald CH; Baumgartner-Parzer S; Trattnig S; Luger A; Krebs M Nutr Metab Cardiovasc Dis; 2016 May; 26(5):387-92. PubMed ID: 27118107 [TBL] [Abstract][Full Text] [Related]
8. FOXO1 contributes to diabetic cardiomyopathy via inducing imbalanced oxidative metabolism in type 1 diabetes. Yan D; Cai Y; Luo J; Liu J; Li X; Ying F; Xie X; Xu A; Ma X; Xia Z J Cell Mol Med; 2020 Jul; 24(14):7850-7861. PubMed ID: 32450616 [TBL] [Abstract][Full Text] [Related]
9. Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes. Ramírez E; Klett-Mingo M; Ares-Carrasco S; Picatoste B; Ferrarini A; Rupérez FJ; Caro-Vadillo A; Barbas C; Egido J; Tuñón J; Lorenzo Ó Cardiovasc Diabetol; 2013 Nov; 12():172. PubMed ID: 24261558 [TBL] [Abstract][Full Text] [Related]
10. Why the diabetic heart is energy inefficient: a ketogenesis and ketolysis perspective. Mishra PK Am J Physiol Heart Circ Physiol; 2021 Oct; 321(4):H751-H755. PubMed ID: 34533402 [TBL] [Abstract][Full Text] [Related]
11. Type 1 diabetic cardiomyopathy in the Akita (Ins2WT/C96Y) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function. Basu R; Oudit GY; Wang X; Zhang L; Ussher JR; Lopaschuk GD; Kassiri Z Am J Physiol Heart Circ Physiol; 2009 Dec; 297(6):H2096-108. PubMed ID: 19801494 [TBL] [Abstract][Full Text] [Related]
13. Aldose reductase inhibition alleviates diabetic cardiomyopathy and is associated with a decrease in myocardial fatty acid oxidation. Gopal K; Karwi QG; Tabatabaei Dakhili SA; Wagg CS; Zhang L; Sun Q; Saed CT; Panidarapu S; Perfetti R; Ramasamy R; Ussher JR; Lopaschuk GD Cardiovasc Diabetol; 2023 Mar; 22(1):73. PubMed ID: 36978133 [TBL] [Abstract][Full Text] [Related]
14. Can We Prevent Mitochondrial Dysfunction and Diabetic Cardiomyopathy in Type 1 Diabetes Mellitus? Pathophysiology and Treatment Options. Cieluch A; Uruska A; Zozulinska-Ziolkiewicz D Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325880 [TBL] [Abstract][Full Text] [Related]
16. Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats. Trang NN; Chung CC; Lee TW; Cheng WL; Kao YH; Huang SY; Lee TI; Chen YJ Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33503985 [TBL] [Abstract][Full Text] [Related]
17. Myocyte membrane and microdomain modifications in diabetes: determinants of ischemic tolerance and cardioprotection. Russell J; Du Toit EF; Peart JN; Patel HH; Headrick JP Cardiovasc Diabetol; 2017 Dec; 16(1):155. PubMed ID: 29202762 [TBL] [Abstract][Full Text] [Related]
18. Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: role of GLP-1 isoforms in Glut4 receptor trafficking. Ramírez E; Picatoste B; González-Bris A; Oteo M; Cruz F; Caro-Vadillo A; Egido J; Tuñón J; Morcillo MA; Lorenzo Ó Cardiovasc Diabetol; 2018 Jan; 17(1):12. PubMed ID: 29325553 [TBL] [Abstract][Full Text] [Related]
19. Counterpoint to the hypothesis that SGLT2 inhibitors protect the heart by antagonizing leptin. Avogaro A; Fadini GP Diabetes Obes Metab; 2018 Jun; 20(6):1367-1368. PubMed ID: 29377537 [No Abstract] [Full Text] [Related]
20. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. An D; Rodrigues B Am J Physiol Heart Circ Physiol; 2006 Oct; 291(4):H1489-506. PubMed ID: 16751293 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]